Yuuwa Capital
Venture capitalPerth · Pre-Seed–Late Stage · 2 people tracked
Investment thesis
Yuuwa is a specialist life sciences commercialisation and investment firm focused on identifying new projects and connecting specialist early-stage investors with high-quality early-stage ventures in the life sciences sector. It provides expertise to help founders and management teams start and scale companies, taking an active role in investing, building and supporting its portfolio companies. Originally established as the manager of a venture capital fund backed by the Australian Federal Government's Innovation Investment Fund program and private investors, the firm draws on deep operator and scientific experience across biotech commercialisation.
Source: firm website, verified Aug 3, 2026.
Team · 2 people
from the firm's websiteJames Williams is a scientist, entrepreneur and investor who has held CEO, CTO and board roles across biotech companies yielding five FDA-approved drugs and devices. He conceived the technology behind iCeutica and co-discovered Dimerix's lead therapy, and holds directorships at PolyActiva, Adalta and Dimerix.
Liddy McCall has over 20 years' experience as a founder, investor and manager of early-stage startups, including co-founding iCeutica, Dimerix and Argus Biomedical, and previously worked at Macquarie Bank on M&A. She is a barrister and solicitor and serves on several Yuuwa investee boards including Argenica Ltd.
Frequently asked questions
- What stage does Yuuwa Capital invest at?
- Yuuwa Capital invests at the Pre-Seed, Seed, Series A, Late Stage stages.
- What sectors does Yuuwa Capital focus on?
- Yuuwa Capital focuses on AgTech, Biotech, Healthtech, Medical Devices.
- Where is Yuuwa Capital located?
- Yuuwa Capital is headquartered in Perth, AU.
Similar investors
DCVC (Data Collective) is a deep tech venture capital firm backing entrepreneurs using computational approaches to solve large real-world problems across many industries. It operates six flagship funds plus DCVC Bio, spanning 13 funds to date.
Novo Holdings A/S is the holding and investment company that manages the assets of the Novo Nordisk Foundation, holding controlling stakes in Novo Nordisk and Novonesis and running a global portfolio of 180+ direct life science investments alongside capital investments.
Forbion is a life sciences investment firm whose portfolio spans therapeutic companies developing treatments for serious diseases as well as planetary health companies advancing sustainable biotech and green chemistry.
Sofinnova Partners provides equity financing for startups and early-stage companies, inviting entrepreneurs to submit projects aligned with one of its fund strategies spanning biopharma, medtech, biotech, industrial biotech and digital medicine.
Artesian is a global alternative investment manager offering early-stage venture capital, fixed income/debt, VC-as-a-Service, impact investing and fund administration. Its VC arm is described as one of Australia's largest and most active early-stage investors.